Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
2561 The University of Texas at San Antonio (144449)
Principal Investigator: McHardy,Stanton F
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 11,722
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 12/15/19 - 11/30/21
Restricted Research: YES
Academic Discipline: Chemistry
Department, Center, School, or Institute: CENTER FOR DRUG DISCOVERY
Title of Contract, Award, or Gift: FOXM1 Inhibition: A Novel Therapeutic Avenue to Treat Breast Cancers 166684/166625
Name of Granting or Contracting Agency/Entity:
University of Texas Health Science Center
CFDA Link: HHS
93.396
Program Title:
none
CFDA Linked: Cancer Biology Research
Note:
SAMS 1.1.1 The goals and objectives of this highly collaborative research project is to develop new, more efficacious and less toxic treatments for aggressive breast cancer patients in general and TNBC patients in particular based on the compound “Imipramine Blue (IB)”, which may serve as a potent therapeutic for treating TNBCs as it induces DNA damage and prevents cancer cells’ ability to repair DNA. UTSA will utilize the SPR, X-Ray and NMR structural data from their collaborators to design novel IB analogs. UTSA will also utilize de Novo design and computational models to support the design of new IB analogs, while simultaneously improving drug-like physical chemical properties (PCP) and ADME characteristics such as permeability, BBB penetration, clearance and pharmacokinetic profiles.
Discussion: No discussion notes